GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Phase 2

Completed

Conditions: Myelofibrosis

Interventions: Drug: Simtuzumab
Drug: Ruxolitinib

First Posted Date: 2011-06-09

Last Posted Date: 2020-07-01

Lead Sponsor: Gilead Sciences

Target Recruit Count: 54

Registration Number: NCT01369498

Locations: 🇺🇸
Stanford University Medical center, Stanford, California, United States
🇺🇸
Oncology Hematology Care Clinical Trials, Cincinnati, Ohio, United States
🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States

and more 4 locations

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Phase 3

Completed

Conditions: Acquired Immunodeficiency Syndrome
HIV Infections

Interventions: Drug: COBI
Drug: E/C/F/TDF
Drug: ATV
Drug: DRV
Drug: NRTI

First Posted Date: 2011-06-01

Last Posted Date: 2016-05-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 106

Registration Number: NCT01363011

Locations: 🇺🇸
Chelsea Village Medical, New York, New York, United States
🇺🇸
Anthony Mills, MD, Inc., Los Angeles, California, United States
🇬🇧
Homerton University Hospital, London, United Kingdom

and more 48 locations

A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis

Phase 1

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: GS-6624

First Posted Date: 2011-05-30

Last Posted Date: 2015-07-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 48

Registration Number: NCT01362231

Locations: 🇺🇸
Loess Hills Clinical Research Center, Council Bluffs, Iowa, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

and more 4 locations

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: GS-5885
Drug: GS-9451
Biological: peginterferon alfa-2a
Drug: ribavirin tablet
Drug: GS-9451 Placebo

First Posted Date: 2011-05-19

Last Posted Date: 2014-02-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 351

Registration Number: NCT01356160

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: GS-5885
Drug: Tegobuvir
Drug: GS-9451
Drug: ribavirin tablet

First Posted Date: 2011-05-13

Last Posted Date: 2013-12-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 141

Registration Number: NCT01353248

Locations: 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States

and more 40 locations

A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

Phase 4

Withdrawn

Conditions: Angina Pectoris
Coronary Artery Disease
Type 2 Diabetes Mellitus

Interventions: Drug: Ranolazine

First Posted Date: 2011-04-13

Last Posted Date: 2012-07-31

Lead Sponsor: Gilead Sciences

Registration Number: NCT01334203

Rollover Protocol Continued Access to Tenofovir Disoproxil Fumarate (TDF) for Subjects in Taiwan

Phase 2

Completed

Conditions: Hepatitis B

Interventions: Drug: Tenofovir DF

First Posted Date: 2011-04-13

Last Posted Date: 2014-03-04

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT01334567

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Sofosbuvir
Drug: RBV
Drug: PEG

First Posted Date: 2011-04-06

Last Posted Date: 2014-05-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 332

Registration Number: NCT01329978

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Asheville Gastroenterology Associates, Asheville, North Carolina, United States
🇺🇸
St. Louis University Gastroenterology and Hepatology Clinical Research, St. Louis, Missouri, United States

and more 43 locations

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: AB0024

First Posted Date: 2011-03-28

Last Posted Date: 2012-05-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 32

Registration Number: NCT01323933

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

Phase 4

Completed

Conditions: Chronic Hepatitis B

Interventions: Other: Stop TDF
Drug: TDF

First Posted Date: 2011-03-23

Last Posted Date: 2017-08-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 43

Registration Number: NCT01320943

Locations: 🇩🇪
Klinikum der LMU Grosshadern, Muenchen, Germany
🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
🇩🇪
Universitaetsklinik Heidelberg, Heidelberg, Germany

and more 10 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy